Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors

Antiviral Research

Volumn 25, Issue 1, 1994, Pages 43-56

  Buckheit Jr , Robert W ^a   Fliakas Boltz, Valerie ^a   Decker, W Don ^a   Roberson, Joseph L ^a   Pyle, Cathi A ^a   White, E Lucile ^a   Bowdon, Bonnie J ^a   McMahon, James B ^b   Boyd, Michael R ^b   Bader, John P ^c   Nickell, David G ^d   Barth, Hubert ^d   Antonucci, Tammy K ^d  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b Laboratory of Drug Discovery Research and Development   (United States)

^c Developmental Therapeutics Program   (United States)

^d PFIZER INC   (United States)

Author keywords

Benzothiadiazine; Combination therapy; Mechanism of action; Nonnucleoside reverse transcriptase inhibitor; Structure activity relationship

Indexed keywords

ANTIVIRUS AGENT; BENZOTHIADIAZINE DERIVATIVE; NSC 287474; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BASE SEQUENCE; BENZOTHIADIAZINES; CELL LINE; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HIV-2; HUMAN; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VIRUS REPLICATION; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MURINAE; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0028043362     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(94)90092-2     Document Type: Article

References (46)

1. Initial studies on the cellular pharmacology of 2–3-dideoxyinosine, an inhibitor infectivity
2. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction
3. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single drug therapy
4. Strategies for the identification of new agents for the treatment of AIDS: a national program to facilitate the discovery and preclinical development of new drug candidates for clinical evaluation
5. HIV-heterogeneity: Characterization of HIV-1 isolates displaying an apparent absence of virion-associated reverse transcriptase activity
6. Thiazolobenzimidazole: Biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor
7. Cell based and biochemical analysis of the anti-HIV activity of combinations of 3′-azido-3′-deoxythymidine and analogs of TIBO
8. Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents
9. Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates
10. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-I reverse transcriptase
11. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors
12. Antiretroviral therapy: Reverse transcriptase inhibition
13. Resistance of human immunodeficiency virus type I reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis
14. Phosphorylation of 3-azido-3-deoxythymidine and selective interaction of the 5-triphosphate with human immunodeficiency virus reverse transcriptase
15. Virus isolation and production
16. Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity
17. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug
18. A semiautomated multiparameter approach for anti-HIV drug screening
19. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree Calophyllum lanigerum
20. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones
21. Synthesis and anti-HIV activity of 4,4,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)on e (TIBO) derivatives
22. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
23. Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type I reverse transcriptase
24. Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficieny virus type 1 reverse transcriptase
25. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase
26. Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor
27. Isolation of a HTLV-III related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys
28. Quantitative infectivity assay for HIV-1 and HIV-2
29. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors
30. Mechanism of inhibition of human immunodeficiency virus reverse transcriptase and human DNA polymerases α, β, γ by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′3′-dideoxyguanosine, and 3′-deoxythymidine
31. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
32. A three-dimensional model to analyze drug-drug interactions
33. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture
34. BI-RG-57 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine
35. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication
36. A short-term clinical evaluation of 1–697, 661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase
37. Inhibition of Gross leukemia virus-induced plaque formation in XC cells by 3-deazauridine
38. Cyclische Sulfoximide, V. 3-Amino-1λ4,2,4-benzothiadiazin-1-oxide
39. New soluble formazan assay for HIV-1 cytopathic effects: application to high flux screening of synthetic and natural products for AIDS antiviral activity
40. TIBO derivatives are potent inhibitors of HIV-1 reverse transcriptase with heteropolymer templates
41. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5′-triphosphates of various anti-HIV nucleoside analogs
42. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site
43. Administration of 3-azido-3-deoxythymidine, an inhibitor of HTLV-III replication, to patients with AIDS and AIDS-related complex
44. In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxycytidine